New immune therapy trial aims to extend life for advanced liver cancer patients
NCT ID NCT05033522
Summary
This study compares a new immunotherapy called AlloStim against standard drug treatments for adults with advanced liver cancer that cannot be treated with surgery or local therapies. The trial aims to see if AlloStim helps patients live longer and have a better quality of life than current medications. It is designed specifically for Asian patients in Thailand and Malaysia, where access to standard treatments can be limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chiangmai University
Chiang Mai, Thailand
-
Columbia Asia Bukit Rimau
Shah Alam, Selangor, 40460, Malaysia
-
Naresuan University Hospital
Phitsanulok, Tha Pho, 65000, Thailand
-
Prince of Songkla University (Songklanagarind Hospital)
Hat Yai, Changwat Songkhla, 90110, Thailand
-
Siriraj Hospital
Bangkok Noi, Bangkok, 10700, Thailand
-
Songklanagarind Hospital
Khon Kaen, Thailand
-
Sultan Ismail Hospital
Johor Bahru, Johor, 81100, Malaysia
-
Sultanah Bahiyah Hospital
Alor Star, Kedah, 05460, Malaysia
Conditions
Explore the condition pages connected to this study.